News Releases

ATLANTA , Nov. 8, 2022 /PRNewswire/ -- Artivion, Inc.   (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.     Artivion's management team will present at the upcoming Stifel 2022

Third Quarter and Recent Business Highlights: Achieved revenue of $76.8 million in the third quarter of 2022 versus $72.2 million in the third quarter of 2021, an increase of 6% on a GAAP basis and 11% on a non-GAAP constant currency basis On-X revenues increased 17% on a GAAP basis and 19% on a

ATLANTA , Oct. 20, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2022 financial results will be released on Thursday, November 3, 2022 after the market closes.

ATLANTA , Sept. 29, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the appointment of Elizabeth A. Hoff to its Board of Directors effective October 1, 2022 .     "We are excited to welcome Elizabeth to our

Study Was Evaluating the Use of Apixaban in Patients Treated with Mechanical Aortic Valves ATLANTA , Sept. 23, 2022 /PRNewswire/ ---   Artivion, Inc. (NYSE: AORT) , a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has stopped the PROACT Xa clinical

ATLANTA , Sept. 14, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present at the upcoming Deutsche Bank 30 th Annual Leveraged Finance Conference on Wednesday, September 21, 2022 .

ATLANTA , Sept. 6, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.     Artivion's management team will present at the upcoming Morgan Stanley 20

ATLANTA , Aug. 24, 2022 /PRNewswire/ --   Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present virtually at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase on Wednesday, August 31, 2022 .

ATLANTA , Aug. 4, 2022 /PRNewswire/ --      Second Quarter and Recent Business Highlights: Achieved revenue of $80.3 million in the second quarter 2022 versus $76.1 million in the second quarter of 2021, an increase of 6% on a GAAP basis and 9% on a non-GAAP constant currency basis Enrolled first

ATLANTA , Aug. 3, 2022 /PRNewswire/ --  Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.     Artivion's management team will present at the upcoming Canaccord Genuity